Junia V. Melo
#149,484
Most Influential Person Now
Junia V. Melo's AcademicInfluence.com Rankings
Junia V. Melobiology Degrees
Biology
#11074
World Rank
#14449
Historical Rank
Molecular Biology
#1667
World Rank
#1695
Historical Rank

Download Badge
Biology
Why Is Junia V. Melo Influential?
(Suggest an Edit or Addition)Junia V. Melo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The molecular biology of chronic myeloid leukemia. (2000) (1641)
- Chronic myeloid leukemia--advances in biology and new approaches to treatment. (2003) (959)
- Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. (2000) (829)
- The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. (1996) (780)
- The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. (1997) (677)
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. (2013) (625)
- Cancer stem cell definitions and terminology: the devil is in the details (2012) (619)
- Chronic myeloid leukaemia as a model of disease evolution in human cancer (2007) (603)
- MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. (2003) (555)
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
- Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. (2002) (535)
- The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. (1998) (442)
- An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. (1994) (283)
- Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR (2010) (279)
- Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (2001) (271)
- Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. (2002) (270)
- Roots of clinical resistance to STI-571 cancer therapy. (2001) (222)
- The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. (2001) (206)
- Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. (2005) (199)
- Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? (2009) (195)
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications (2008) (194)
- Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. (1987) (180)
- Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. (2004) (172)
- Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. (2003) (170)
- Natural course and biology of CML (2015) (170)
- The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia (1986) (169)
- The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib (2006) (165)
- Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. (2007) (161)
- p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. (1996) (159)
- Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprogramming (2010) (158)
- Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. (2006) (155)
- P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? (1994) (155)
- BCR-ABL gene variants. (1997) (154)
- The ABL-BCR Fusion Gene Is Expressed in Chronic Myeloid Leukemia (1993) (152)
- The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. (2007) (151)
- BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. (2000) (142)
- A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. (1996) (139)
- Resistance to imatinib mesylate in chronic myeloid leukaemia. (2007) (132)
- Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. (2002) (132)
- Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis (2007) (128)
- A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. (2006) (119)
- Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro (2004) (118)
- Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. (2001) (116)
- Cytogenetic studies on prolymphocytic leukemia. 1. B-cell prolymphocytic leukemia. (1987) (116)
- In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. (2004) (108)
- Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. (2003) (104)
- Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells (2008) (104)
- Cytogenetic and Molecular Genetic Aspects of Chronic Myeloid Leukaemia (2002) (104)
- Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia (2007) (102)
- The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia (1986) (102)
- Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells (2009) (102)
- Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG (2005) (99)
- BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry (2006) (94)
- Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. (1984) (92)
- In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. (2010) (90)
- A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. (2010) (88)
- Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. (1998) (86)
- Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia (2005) (81)
- Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. (1987) (81)
- Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. (2002) (80)
- Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. (2002) (80)
- Chronic myeloid leukemia. (2003) (79)
- Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. (2003) (78)
- The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia (1986) (77)
- The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia (1987) (76)
- Chromosome abnormalities at 11q13 in B cell tumours (1988) (75)
- Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. (2001) (74)
- Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition (2017) (70)
- Two new cell lines from B‐prolymphocytic leukaemia: Characterization by morphology, immunological markers, karyotype and Ig gene rearrangement (1986) (70)
- BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work? (2008) (68)
- Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway (2010) (63)
- Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells (2005) (62)
- Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. (2008) (62)
- Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. (2010) (61)
- Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. (2012) (61)
- Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells (2009) (61)
- Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. (2001) (60)
- Analysis of genomic breakpoints in p190 and p210 BCR–ABL indicate distinct mechanisms of formation (2010) (59)
- The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. (1993) (59)
- Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors (2010) (59)
- Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. (2003) (57)
- Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. (2007) (57)
- Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. (1994) (57)
- BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. (1995) (55)
- Lack of correlation between ABL‐BCR expression and response to interferon‐α in chronic myeloid leukaemia (1996) (53)
- SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. (2011) (51)
- Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. (2002) (51)
- Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. (1996) (46)
- Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease (2004) (46)
- Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene (2001) (45)
- Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. (2005) (43)
- Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571 (2002) (43)
- The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. (1988) (42)
- The membrane phenotype of hairy cell leukemia: a study with monoclonal antibodies. (1984) (42)
- ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. (2001) (42)
- The 14q+ marker in hairy cell leukaemia. A cytogenetic study of 15 cases. (1986) (42)
- BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis (2003) (41)
- Morphology and immunology of circulating cells in leukaemic phase of follicular lymphoma. (1988) (38)
- Overcoming STI 571 resistance with the farnesyl transferase inhibitor SCH 66336 (2002) (38)
- Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. (2000) (38)
- Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia. (1993) (38)
- Do we have to kill the last CML cell? (2011) (37)
- The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia (2007) (37)
- Mechanisms of resistance to BCR–ABL kinase inhibitors (2011) (36)
- Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? (2011) (34)
- Upregulation of the TGFβ signalling pathway by Bcr‐Abl: Implications for haemopoietic cell growth and chronic myeloid leukaemia (2007) (34)
- Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. (2002) (33)
- Establishment and characterization of three new malignant lymphoid cell lines (1987) (32)
- Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies. (2003) (32)
- Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate (2003) (32)
- The polycomb group BMI 1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia (2007) (31)
- Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy (2010) (31)
- Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. (2008) (29)
- The leukocyte-common antigen (CD45) complex and B-lymphocyte activation. (1990) (28)
- The impact of gene profiling in chronic myeloid leukaemia. (2009) (28)
- A kinase-independent role for CDK8 in BCR-ABL1+ leukemia (2019) (27)
- Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia (2018) (26)
- Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5 (2013) (26)
- Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib (2006) (23)
- Proteasome proteolytic profile is linked to Bcr-Abl expression. (2009) (22)
- Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. (2015) (21)
- Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells (2012) (21)
- Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. (1996) (20)
- Management of chronic myeloid leukemia: targets for molecular therapy. (2003) (20)
- Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients (2013) (20)
- Production of P‐glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first‐line chemotherapy in advanced breast cancer (2007) (19)
- Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. (2011) (19)
- Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1 (2009) (19)
- Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia (2014) (19)
- Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach. (2010) (18)
- CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. (2009) (18)
- Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines (2007) (18)
- Inviting leukemic cells to waltz with the devil (2001) (18)
- Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models (2014) (18)
- Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. (2005) (18)
- Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. (2007) (17)
- Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia (2006) (17)
- Biological Markers in Lymphoproliferative Disorders (1985) (17)
- Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia (2010) (17)
- Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts. (1994) (16)
- A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL (2013) (15)
- Primary plasma cell leukaemia: immunological and ultrastructural studies in 6 cases. (2009) (15)
- Prolymphocytic leukemia of B cell type: rearranged immunoglobulin (Ig) genes with defective Ig production. (1985) (15)
- Chronic lymphocytic leukemia and prolymphocytic leukemia: a clinicopathological reappraisal. (1987) (15)
- Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient (2012) (15)
- Overproduction of BCR‐ABL induces apoptosis in imatinib mesylate‐resistant cell lines (2005) (14)
- Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells (2009) (14)
- Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells (2007) (14)
- The susceptibility of Philadelphia chromosome positive cells to FAS‐mediated apoptosis is not linked to the tyrosine kinase activity of BCR‐ABL (1998) (13)
- The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib (2009) (13)
- BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir. (2001) (12)
- Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules. (1987) (12)
- Splenectomy in advanced chronic lymphocytic leukaemia. (1987) (12)
- SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function (2011) (12)
- Lack of imprinting of the ABL gene (1994) (12)
- Imatinib: can one outwit chronic myeloid leukemia? (2002) (12)
- Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. (2007) (11)
- Chronic myeloid leukemia – some topical issues (2007) (11)
- Different reactivity of monoclonal antibodies against common acute lymphoblastic leukaemia antigen (CD10). (1987) (11)
- BCR‐ABL‐positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions (1996) (11)
- The Biology and Pathogenesis of Chronic Myeloid Leukemia (2016) (11)
- Do we have to kill the last CML cell? (2011) (11)
- Cross‐resistance of imatinib mesylate and 17‐aag in imatinib‐resistant cells that overexpress bcr‐abl (2003) (10)
- Reply to ‘What do we mean by sensitivity when we talk about detecting minimal residual disease?’ by Steinbach and Debatin (2009) (10)
- Nuclear positioning of the BACH2 gene in BCR‐ABL positive leukemic cells (2007) (10)
- Reactivity of the monoclonal antibody RFB1 in chronic B-cell leukaemias. (2009) (10)
- BCR‐ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia (2012) (9)
- Intracytoplasmic inclusions in B prolymphocytic leukaemia: ultrastructural, cytochemical, and immunological studies. (1985) (9)
- Imatinib and ABCG2: who controls whom? (2006) (9)
- Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrowand mobilised peripheral blood (2000) (8)
- Restoration of sensitivity to STI 571 in STI 571-resistant chronic myeloid leukemia cells (2001) (8)
- Chronic myeloid leukemia: the basis of treatment for tomorrow (2011) (8)
- Antigenic expression of B-cell chronic lymphocytic leukemic cell lines. (1992) (8)
- The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells (2017) (8)
- In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis. (2007) (8)
- Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia. (1992) (7)
- Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib (2009) (7)
- Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma (2000) (7)
- BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations. (2006) (6)
- Response of STI571-resistant cells to other chemotherapeutic drugs and signal transduction inhibitors. (2000) (6)
- Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients (2013) (6)
- Modulation of the p 38 MAPK ( mitogen-activated protein kinase ) pathway through Bcr / Abl : implications in the cellular response to AraC (2005) (6)
- One Year into the COVID-19 Pandemic (2021) (5)
- Chronic Myeloid Leukemia: Biology of Advanced Phase (2007) (5)
- Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment. (2006) (5)
- Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia. (1995) (5)
- Expression of the LH2 gene in chronic myeloid leukaemia cells. (1996) (5)
- Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells (2013) (5)
- Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia (2016) (5)
- Handbook of Chronic Myeloid Leukemia (2014) (4)
- A Gene Expression Signature of CD34+Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance (2009) (4)
- The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. (2017) (4)
- Molecular profiling of CD34+ cells identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival in CML patients (*) (2005) (3)
- Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia blast crisis (2000) (3)
- Myeloid Leukemia of Multiple Genes Implicated in the Pathogenesis of Chronic Tyrosine Kinase Activity Regulates the Expression BCR-ABL Updated (2000) (3)
- Novel compounds with antiproliferative activity against imatinib-resistant cell lines (2007) (3)
- Zoledronate is active against imatinib mesylate-resistant chronic myeloid leukemia cell lines and synergistic/additive when combined with imatinib mesylate. (2003) (3)
- Advances in Brief Bcr-Abl Kinase Modulates the Translation Regulators Ribosomal Protein S 6 and 4 EBP 1 in Chronic Myelogenous Leukemia Cells via the Mammalian Target of Rapamycin 1 (2003) (3)
- Chronic Myeloid Leukaemia (2015) (2)
- The Proteome Analysis of an Imatinib-Resistant Cell Line Identifies Changes in Molecular Chaperones Such as Heat Shock Proteins (Hsp): A Possible New Mechanism of Imatinib Resistance. (2004) (2)
- Monitoring Response to Treatment (2014) (2)
- Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH‐296 (1999) (2)
- Management of Patients with Chronic Myeloid Leukemia (2014) (2)
- When is a double Philadelphia not a double Philadelphia (2007) (2)
- Wrapping BCR-ABL: it's in the bag. (2010) (2)
- B Prolymphocytic Leukemia Cell Lines: Phenotype and Response to B Cell Differentiation Factor (1988) (1)
- Molecular Basis of Chronic Myeloid Leukaemia (2003) (1)
- How cured are CML patients in complete molecular remission (CMR) after stem cell transplantation or imatinib (2007) (1)
- The human leucocyte P30 antigen: properties and assessment of value as a clonal marker. (2008) (1)
- Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT). (2007) (1)
- RUNX1 mutations are rare in chronic phase polycythaemia vera (2011) (1)
- Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival. (2005) (1)
- Metabolic Profile of Imatinib Resistance in CML Cells. (2004) (1)
- Neoplastic kappa and lambda cells in a B-PLL with chromosome translocations of both light chain gene regions. (1984) (1)
- Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Bcr-Abl Positive Cells. (2006) (1)
- Specific action of FGFR inhibitors against t(4;14) positive myeloma cells (2001) (1)
- Myeloid Leukemia Development of Resistance to Imatinib Mesylate in Chronic Bcr-Abl Expression Levels Determine the Rate of Updated (2005) (1)
- The Biology and Pathogenesis of Chronic Myeloid Leukaemia (2021) (1)
- Gains and amplifications of the ABL-NUP214 region in blast stage of CML (2007) (0)
- Subject Index Vol. 119, 2008 (2008) (0)
- High-Dose Ionizing Radiation Selective Induction of Leukemia-associated Fusion Genes by Updated (2006) (0)
- Bcr-Abl Positive Cells Display Increased Proteasome Activity and Greater Sensitivity to Proteasome Inhibition (2008) (0)
- Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. (2009) (0)
- Comparative gene expression profile of p185(Bcr-Abl) versus p210(Bcr-Abl) expressing cells. (2004) (0)
- The molecular biology of chronic myeloid leukaemia. (1996) (0)
- Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity. (2004) (0)
- To the Editor. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia (2001) (0)
- Reply to ‘Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?’ by Chunduri et al (2005) (0)
- Novel pathway in BCR-ABL signal transduction involves Akt-independent activation of PLC-gamma/mTOR/P70-S6 kinase (2007) (0)
- Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis (2011) (0)
- Repetitive washing prevents apoptosis after high-dose TKI pulse-exposure. (2012) (0)
- Pathophysiology of Chronic Myeloid Leukemia (2011) (0)
- Transcriptional Regulation of the Bach2 B-Cell Differentiation and Apoptotic Factor by the Bcr-Abl Oncoprotein. (2005) (0)
- Inactivation of HOXAGenes by Hypermethylation in Myeloid and LymphoidMalignancy is Frequent and Associated with Poor Prognosis (2007) (0)
- Leukemia Cells via the Mammalian Target of Rapamycin Ribosomal Protein S 6 and 4 EBP 1 in Chronic Myelogenous Bcr-Abl Kinase Modulates the Translation Regulators (2003) (0)
- A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment (2008) (0)
- ORIGINAL ARTICLE BCR-ABL activity and its response to drugs can be determined in CD34 þ CML stem cells by CrkL phosphorylation status using flow cytometry (2006) (0)
- leukemia cells Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid (2013) (0)
- Reply to Haas: Are ABL and BCR imprinted? (Leukemia 1995; 9: 740-743). (1995) (0)
- The gene expression profile of CML CD34+ cells can predict the duration of chronic phase. (2003) (0)
- P-122 Transfusion dependency is associated with inferior outcome in very low- and low-risk IPSS-R patients (2013) (0)
- Challenges of Treatment: Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia (2014) (0)
- Resistance to imatinib mesylate in CML: all BCR-ABL mutations “are created equal but some are more equal than others” (2003) (0)
- OTT-3971-Targeted treatment of imatinib-resistant chronic my (2009) (0)
- Multiple molecular mechanism may account for resistance to imatinib in resistant cell lines (2007) (0)
- prognosis of chronic myeloid leukemia The polycomb group BMI-1 gene is a molecular marker for predicting (2013) (0)
- Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia (2015) (0)
- with imatinib response in chronic-phase chronic myeloid leukemia patients treated cells to predict major cytogenetic + A gene expression signature of CD34 (2011) (0)
- leukemia cell line models MDR1 gene overexpression confers resistance to imatinib mesylate in (2013) (0)
- reduced antigen processing, and impaired migration Dendritic cells from CML patients have altered actin organization, (2013) (0)
- Chronic myeloid leukemia: the possibility of a cure (2013) (0)
- BCR-ABL-Induced Downregulation of GADD45G in Chronic Myeloid Leukemia (2012) (0)
- Activation of the P38 MAPK Pathway Mediates Resistance to Ara-C y Bcr/Abl Positive Cells. (2005) (0)
- SCH66336 Overcoming STI571 resistance with the farnesyl transferase inhibitor (2013) (0)
- Contents Vol. 119, 2008 (2008) (0)
- Short –Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+ Cells Unless They Are Growth Factor Deprived. (2008) (0)
- Glutathione-Depletion Potently Enhances the Cytotoxic Activity of Arsenic Trioxide in Imatinib Sensitive and Resistant Bcr-Abl Positive Cell Lines. (2004) (0)
- Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment. (2007) (0)
- Targeting Isoprenylcysteine Carboxyl Methyltransferase to Overcome Resistance and Improve Responses in Chronic Myeloid Leukemia. (2009) (0)
- Monitoring CML after nonmyeloablative transplantations: how negative is negative? (2003) (0)
- Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. (2009) (0)
- RESEARCH PAPER Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells (2009) (0)
- HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia. (2007) (0)
- Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib. (2005) (0)
- Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL). (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Junia V. Melo?
Junia V. Melo is affiliated with the following schools: